Affinity Asset Advisors’s Tango Therapeutics TNGX Stock Holding History

Affinity Asset Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,000,000	Closed	-$8.86M	–	118
2025 Q4	$8.86M	Buy	+1,000,000	New	+$8.62M	0.5%	48
2024 Q3	–	Sell	-150,274	Closed	-$1.29M	–	105
2024 Q2	$1.29M	Hold	150,274	–	–	0.15%	77
2024 Q1	$1.19M	Sell	150,274 -150,000	-50%	-$1.61M	0.15%	80
2023 Q4	$2.97M	Sell	300,274 -49,726	-14%	-$432K	0.54%	48
2023 Q3	$3.94M	Buy	+350,000	New	+$2.13M	1.11%	31
2022 Q4	–	Sell	-81,982	Closed	-$297K	–	81
2022 Q3	$297K	Buy	+81,982	New	+$350K	0.08%	61
2021 Q4	–	Sell	-50,000	Closed	-$647K	–	72
2021 Q3	$647K	Sell	50,000 -50,000	-50%	-$599K	0.16%	65
2021 Q2	$1.14M	Hold	100,000	–	–	0.41%	51
2021 Q1	$1.11M	Hold	100,000	–	–	0.38%	47
2020 Q4	$1.14M	Buy	+100,000	New	+$1.05M	0.61%	39

Other funds holding TNGX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Affinity Asset Advisors's TNGX Position: Q1 2026 in Review

Affinity Asset Advisors sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 1,000,000 shares — an estimated $8.86M sold.

Affinity Asset Advisors first reported a position in TNGX in Q4 2020 and held it in 10 quarters. The position peaked at $8.86M in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

Affinity Asset Advisors reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
Affinity Asset Advisors sold 1,000,000 Tango Therapeutics shares in Q1 2026, an estimated $8.86M.
Affinity Asset Advisors first reported a position in Tango Therapeutics in Q4 2020 and held it in 10 quarters.
Affinity Asset Advisors's Tango Therapeutics position peaked at $8.86M in Q4 2025.
194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.